Interval Cancers Down With Digital Breast Tomosynthesis
WEDNESDAY, April 7, 2021 -- Women undergoing screening with digital breast tomosynthesis (DBT) have a lower interval cancer rate compared with those screened with digital mammography (DM) alone, according to a study published online April 6 in Radiology.
Kristin Johnson, M.D., from Skåne University Hospital in Malmö, Sweden, and colleagues compared interval cancer rates and tumor characteristics in DBT screening to those in a population screened with DM. Data were included for 14,848 women screened with DBT and DM in the prospective population-based Malmö Breast Tomosynthesis Screening Trial (MBTST) between January 2010 and February 2015. A total of 13,369 women in the trial were compared to a matched control group of 26,738 women of the same age and screening occasion screened with DM at the same center.
The researchers found that the interval cancer rate was 1.6 per 1,000 screened women in the MBTST compared with 2.8 per 1,000 screened women in the control group (conditional odds ratio, 0.6). In general, high Ki-67 status was seen in invasive interval cancers in the MBTST and control groups (63 and 75 percent, respectively), while the proportions of luminal A-like subtype were low (26 and 17 percent, respectively).
"One could speculate that some of the additional cancers detected in DBT screening would have been diagnosed as interval cancers if not detected by DBT," Johnson said in a statement.
Several authors disclosed financial ties to the medical device, medical technology, and publishing industries.
© 2021 HealthDay. All rights reserved.
Posted: April 2021
Read this next
TUESDAY, April 13, 2021 -- Countries should suspend the sale of live wild animals at food markets because they are a leading source of emerging infectious diseases such as...
TUESDAY, April 13, 2021 -- Both use of fall risk-increasing drugs and mortality due to falls are on the rise in older adults, according to a study recently published online in...
TUESDAY, April 13, 2021 -- With the support of experts from the Uniformed Services University, diagnostic criteria have been developed for traumatic encephalopathy syndrome (TES),...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.